Fingolimod
Top View
- Fingolimod-Associated Macular Edema (FAME) in the Treatment of Multiple Sclerosis I. Case History • Patient Demographics: O 61
- Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
- Estonian Statistics on Medicines 2013 1/44
- Gilenya (Fingolimod) Aubagio (Teriflunomide) Tecfidera (BG-12)
- Analyses of Spontaneous Adverse Drug Reaction Databases Using Descriptive and Inferential Statistics
- Celgene Bets Big on Scripps-Originated Autoimmunity Candidate
- Tysabri® (Natalizumab Injection for Intravenous Use – Biogen)
- Real World Comparison of Patient Multiple Adherence and Persistence to Sclerosis Fingolimod Vs
- ALEMTUZUMAB/FINGOLIMOD/NATALIZUMAB for Multiple Sclerosis
- The Development of Fingolimod (FTY720, Gilenya)
- Cladribine Tablets
- Fingolimod for the Treatment of Multiple Sclerosis: a Review of the Evidence from the FREEDOMS and TRANSFORMS Studies
- Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis
- Ozanimod 0.5 Mg Or 1 Mg Ozanimod Daily, Or Weekly Injections of Interferon Beta-1A
- Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: a Systematic Review on Immune Response and Vaccination Recommendations
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- View Transcript
- Cutaneous Side Effects of First / Second Line Oral Disease - Modifying Treatments in Patients with Multiple Sclerosis